5Z-7-Oxozeanol Inhibits the Effects of TGFβ1 on Human Gingival Fibroblasts

Hanna Kuk¹, James Hutchenreuther¹, Hannah Murphy-Marshman², David Carter³, Andrew Leask¹,² *

¹ Department of Physiology and Pharmacology, The University of Western Ontario, Schulich School of Medicine and Dentistry, London, Ontario, Canada, N6A 5C1, ² Department of Dentistry, The University of Western Ontario, Schulich School of Medicine and Dentistry, London, Ontario, Canada, N6A 5C1, ³ London Regional Genomics Centre, Robarts Research Institute, London, ON, Canada, N6A 5B7

* Andrew.Leask@schulich.uwo.ca

Abstract

Transforming growth factor (TGF)β acts on fibroblasts to promote the production and remodeling of extracellular matrix (ECM). In adult humans, excessive action of TGFβ is associated with fibrotic disease and fibroproliferative conditions, including gingival hyperplasia. Understanding how the TGFβ1 signals in fibroblasts is therefore likely to result in valuable insights into the fundamental mechanisms underlying fibroproliferative disorders. Previously, we used the TAK1 inhibitor (5Z)-7-Oxozeaenol to show that, in dermal fibroblasts, the non-canonical TAK1 pathway mediates the ability of TGFβ1 to induce genes promoting tissue remodeling and repair. However, the extent to which TAK1 mediates fibroproliferative responses in fibroblasts in response to TGFβ1 remains unclear. Herein, we show that, in gingival fibroblasts, (5Z)-7-Oxozeaenol blocks the ability of TGFβ1 to induce expression of the pro-fibrotic mediator CCN2 (connective tissue growth factor, CTGF) and type I collagen protein. Moreover, genome-wide expression profiling revealed that, in gingival fibroblasts, (5Z)-7-Oxozeaenol reduces the ability of TGFβ1 to induce expression of essentially all TGFβ1-responsive genes (139/147), including those involved with a hyperproliferative response. Results from microarray analysis were confirmed using real time polymerase chain reaction analysis and a functional cell proliferation assay. Our results are consistent with the hypothesis that TAK1 inhibitors might be useful in treating fibroproliferative disorders, including that in the oral cavity.

Introduction

Wound healing is a highly regulated process that occurs in all tissues and organs of the body in response to injury. Excessive deposition and remodeling of connective tissue can result in fibroproliferative conditions [1], which, in adult tissues, can be characterized by the presence of scar tissue or pathological fibrosis. Scars replace normal tissue architecture thus diminishing the function of the tissue or organ. It is estimated that 45% of deaths in the developed countries are attributed to some form of pathological fibrosis [2]. The effector cell of pathological...
scarring is the myofibroblast, a type of fibroblast characterized by the presence of α smooth muscle actin (SMA)-containing stress fibers [3]. Intriguingly, fibrotic responses in the oral cavity do not involve either the deposition of scar tissue or the presence of abundant myofibroblasts, but are instead characterized by an excessive hyperproliferative response that results in gingival overgrowths, for example, in response to antiepileptic medications, calcium channel blockers and immunosuppressant drugs [4]. Thus comparing the signaling responses of dermal and gingival fibroblasts to fibrogenic stimuli is of inherent value.

TGFβ1 is a potently fibrogenic growth factor which promotes the ability of fibroblasts to proliferate, migrate, deposit and remodel newly formed extracellular matrix (ECM). TGFβ1-mediated signaling involves both canonical (Smad-dependent) and non-canonical (Smad-independent) pathways [5]. The former mediates essentially all cellular responses to TGFβ1 [5]. For example, previously we and others have shown that the canonical ALK5/Smad3 pathway mediates pro-fibrotic responses to TGFβ in a variety of fibroblasts, including the ability of TGFβ to induce expression of the profibrotic marker CCN2 in both dermal and gingival fibroblasts [6–10].

One non-canonical TGFβ pathway is mediated by TGFβ-associated kinase 1 (TAK1), a mitogen-activated kinase kinase kinase (MAP3K), which is crucial for the activation of the p38 and JNK MAPK pathways [11]. In human adult dermal and mouse embryonic fibroblasts, TAK1 pathway selectively mediates adhesive, migratory, proliferative and contractile responses to TGFβ1 [12, 13]. Genome-wide expression profiling showed that the TAK1 inhibitor (5Z)-7-Oxozeaenol blocked the induction of ~70% of the TGFβ1-responsive mRNAs in human adult dermal fibroblasts [13]. However, whether TAK1 mediates the fibroproliferative responses to TGFβ1 in gingival fibroblasts is unknown.

To address this gap in our knowledge, in this report we test whether the selective TAK1 inhibitor 5Z-7-Oxozeanol inhibits the ability of TGFβ1 to induce fibroproliferative responses in cultured gingival fibroblasts.

Methods

Cell Culture and Ethics Statement

Previously isolated gingival fibroblast cells generated according to an approved ethical protocol at the University of Western Ontario [6] were grown in high glucose DMEM, 10% FBS and 1% antibiotic-antimycotic (Invitrogen) at 37°C, 5% CO2. Cells were cultured in 96 well plates (for proliferation assays) or 6 well plates (for all other assays) until 40–60% confluence. Cells were then cultured overnight in low glucose DMEM, 0.5% FBS, and pre-treated with DMSO or 400 nM (5Z)-7-Oxozeaenol (Tocris; a concentration previously shown to be selective for TAK1 [13–15]) for 45 minutes prior to treatment with or without TGFβ1 (4 ng/ml, R&D systems). Cultures of passages 8 through 10 were utilized for this study.

RNA Extraction and Real-Time RT-qPCR

Real time PCR was conducted essentially as previously described [6]. Total RNAs were extracted (Trizol, Invitrogen) 6 hours post-addition of TGFβ1 and the concentration and integrity of the extracted RNA sample was measured using a Nanodrop 2000 (Thermo) and Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA) using the RNA 6000 Nano kit (Caliper Life Sciences, Mountain View, CA). The extracted RNA samples (50 ng) were reversed transcribed and amplified using TaqMan Human gene Expression assays (Applied Biosystems) in a 15-μL reaction containing qScript™ XLT One-Step RT-qPCR ToughMix (Quanta Biosciences) TaqMan Assays-on-demand Human gene specific primers (Applied Biosystems), 6-carboxyfluoresceinlabeled gene specific TaqMan MGB probe (Applied Biosystems). The ViiA™ 7
Real-Time PCR System and ViiA™ 7 Software were used for the detection and analysis of the amplified signal according to manufacturer’s instructions (Applied Biosystems). Triplicate samples were run, and experiments were repeated on three independent occasions, and averages +/- SEM (N = 3) calculated. Single factor ANOVA and Tukey’s Post Hoc analysis were used for statistical analysis (GraphPad Prism software).

Western Blot Analysis
Proteins were harvested 24 hours post-addition of TGFβ1 in RIPA buffer (100 mM Tris HCl, pH 7.4; 150 mM NaCl; 1% NP40; 0.1% SDS; 5 mM EDTA, 1X PMSF, 1X protease inhibitor cocktail) and total protein concentration of the lysates was established using the BCA assay microplate procedure as per manufacturer instructions (Pierce). When phosphoproteins were to be detected, protein extraction in the presence of 1mM Sodium orthovanadate, 1mM sodium fluoride, and 2.5mM β-glycerolphosphate was performed. Proteins (50 μg) were then subjected to SDS-PAGE using a 10% acrylamide gel. Gels were then transferred onto nitrocellulose membrane (iBlot; Invitrogen). The resultant membranes were incubated for 1 hour in Blocking buffer solution (50 mM Tris, 150 mM NaCl; 0.05% Tween-20; 5% skim milk) followed by the addition of anti-CCN2 (L-20) goat polyclonal primary antibody (1:250; Santa Cruz Biotechnology) or anti-type I collagen antibody (1:4000) and subsequent overnight incubation at 4°C. Alternatively, blots were probed with anti-phospho-TAK1 antibody (1:1000; Abcam). Membranes were washed three times in TBST at room temperature for 10 min and incubated with an anti-goat secondary HRP conjugated polyclonal antibody (1:2000; Jackson Immunoresearch) for one hour at room temperature and imaged on X-ray film (Kodak) with the use of Chemiluminescent Substance (1:1 Lumino/Enhancer solution to Stable Peroxide Solution ratio; Thermo Scientific). Membranes were subsequently washed in TBST and stripped with the Restore western blot stripping buffer (Thermo) for 20 min at room temperature, blocked and re-probed with β-actin mouse monoclonal primary antibody (Sigma; 1:8000 dilution) overnight at 4°C in TBST prior to exposure with appropriate HRP conjugated secondary antibody. Densitometry measures for band intensities for TGFβ1 and TGFβ1+(5Z)-7-Oxozeaenol treatment groups were obtained using ImageJ program (NIH) and standardized to the respective β-actin levels. Student’s t-test was used for statistical analysis (GraphPad Prism software).

Indirect Immunofluorescence Analysis
Cells cultured on glass coverslips (VWR) were fixed in 4% paraformaldehyde in PBS, permeabilized with 0.2% TritonX100 (Sigma-Aldrich) in PBS and blocked with 5% Donkey serum in PBST (10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl, 0.05% Tween 20; pH 7.4) for 30 min at room temperature followed by the addition of CCN2 (L-20) goat polyclonal antibody (1:100; Santa Cruz Biotechnology). Following one hour incubation at room temperature, the samples were washed in PBS and incubated with DyLight 594 anti-goat IgG secondary antibody in 5% Donkey serum in PBST for 45 min at room temperature in the dark (1:1000; Jackson ImmunoResearch Laboratories). The coverslips were mounted on the slides using VECTASHIELD Mounting Media (Vector Laboratories). Images were taken with a Zeiss Axio Imager.M1 microscope and Northern Eclipse software. Total fluorescence intensity was obtained for each individual image and divided by the representative cell number using DAPI stain as a guide. Relative fluorescence intensity ratio was further obtained using DMSO treatment group as a standard. Single factor ANOVA and Tukey’s Post Hoc analysis were used for statistical analysis (GraphPad Prism software).
Gene Expression Profiling

Gene expression profiling was conducted essentially as previously described [13]. All sample labeling and GeneChip processing was performed at the London Regional Genomics Centre (Robarts Research Institute, London, Ontario, Canada; http://www.lrgc.ca). RNA quality was assessed using the Agilent 2100 Bioanalyzer (Agilent) and the RNA 6000 Nano kit (Caliper Life Sciences). Single stranded complimentary DNA (sscDNA) was prepared from 200 ng of total RNA as per the Ambion WT Expression Kit for Affymetrix GeneChip Whole Transcript WT Expression Arrays (http://www.ambion.com/techlib/prot/fm_4411973.pdf, Applied Biosystems, Carlsbad, CA) and the Affymetrix GeneChip WT Terminal Labeling kit and Hybridization User Manual (http://media.affymetrix.com/support/downloads/manuals/wt_term_label_ambion_user_manual.pdf, Affymetrix, Santa Clara, CA). Total RNA was first converted to cDNA, followed by in vitro transcription to make cRNA. 5.5 μg of single stranded cDNA was synthesized, end labeled and hybridized, for 16 hours at 45°C, to Human Gene 1.0 ST arrays. All liquid handling steps were performed by a GeneChip Fluidics Station 450 and GeneChips were scanned with the GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, CA) using Command Console v1.1. Probe level (.CEL file) data was generated using Affymetrix Command Console v1.1. Probes were summarized to gene level data in Partek Genomics Suite v6.6 (Partek, St. Louis, MO) using the RMA algorithm (Irizarry et al., 2003). Partek was used to determine gene level ANOVA p-values and fold changes. Per previous publications [13, 16], gene lists were created using a filter of 1.7 fold change and p-value of $< 0.05$. Gene Ontology enrichment was performed using a Fisher’s Exact test. GEO accession number is GSE65069.

Proliferation Assay

For the cell proliferation assay, cells (500 cells/well) were seeded in 96-well plates (Greiner Bio-One) and cultured for one day in high glucose DMEM media, 10% FBS. A “no-cell control” was also used, involving media alone. Cultures were serum-starved (low glucose DMEM; 0.5% FBS) overnight, pre-treated with DMSO (vehicle control) or 400 nM (5Z)-7-Oxozeaenol for 45 minutes, and then treated with or without TGFβ1 (4 ng/ml). BrdU reagent (1X, Cell Signalling) was then added to all treatment groups. Each treatment group consisted of 4 separate wells. Cultures were incubated for zero, 24, 48 and 72 hours and subjected to a colorimetric BrdU proliferation assay (Cell Signalling) and absorbance values reading obtained at 450 nm was calculated (iMark microplate absorbance reader, BioRad). Values obtained from the “no-cell control” was subtracted from each individual well. The experiment was repeated two additional times for a total of three times. A representative experiment in shown. Repeated measures ANOVA and Tukey’s Post Hoc analysis were used for statistical analysis (GraphPad Prism software).

Results

(5Z)-7-Oxozeaenol reduces the ability of TGFβ1 to induce CCN2 and type I collagen mRNA and protein expression in gingival fibroblasts

To begin to determine whether the TAK1-mediated non-canonical TGFβ signaling pathway operates in gingival fibroblasts, we first assessed whether the ability of TGFβ to induce CCN2 in gingival fibroblasts was blocked by TAK1 inhibition. We performed this analysis as an initial screening tool as CCN2, a member of the CCN family of matricellular proteins, serves as a marker and a mediator of fibrogenic responses and is highly induced by TGFβ1 [9, 17–19]. To assess whether (5Z)-7-Oxozeaenol, a TAK1 selective inhibitor, reduced TGFβ1-induced CCN2 expression in gingival fibroblasts, we initially used real time PCR analysis to detect CCN2
mRNA. TGFβ1 (6 hours, 4 ng/ml) significantly up-regulated CCN2 mRNA levels in gingival fibroblasts, (Fig 1). Pre-treatment of gingival fibroblasts with (5Z)-7-oxozeaenol 45 minutes prior to addition of TGFβ1 significantly reduced the ability of TGFβ1 to induce CCN2 mRNA expression (Fig 1). Results were verified using Western blot analysis to detect CCN2 protein (24 h treatment with 4 ng/ml TGFβ) (Fig 2A). Similarly, indirect immunofluorescence analysis of cells using an anti-CCN2 antibody revealed that TGFβ1 (24 h treatment with 4 ng/ml TGFβ) led to an accumulation of intracellular CCN2 that was reduced by (5Z)-7-Oxozeaenol (Fig 2B). Similarly, TGFβ-induced type I collagen protein in gingival fibroblasts was sensitive to (5Z)-7-Oxozeaenol (Fig 3A). Conversely, TGFβ1 was unable to appreciably induce COL1A1 and COL1A2 mRNAs (Fig 3B), consistent with prior data that gingival fibroblasts are relatively insensitive to TGFβ1 [16] and that TGFβ1 does not potently induce COL1A1 and COL1A2 mRNAs in fibroblasts and that posttranscriptional regulation appears to be primarily responsible for TGFβ1-induced collagen type I protein expression in fibroblasts [13, 16, 20]. Consistent with this notion, TGFβ1 elevated mRNA expression of the collagen modifying enzyme

![CCN2 mRNA expression](image-url)
procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD)2, which promotes collagen stability, in a (5Z)-7-oxozeaenol-sensitive fashion (Fig 3B). These results suggest that the TAK1 pathway not only operates in gingival fibroblasts but is also required for TGFβ1-induced CCN2 and collagen type I expression. These results are consistent with the notion that the TAK1 pathway may mediate fibroproliferative responses to TGFβ in gingival fibroblasts.
(5Z)-7-Oxozeaenol reduces the induction of essentially all TGFβ1-responsive mRNAs in gingival fibroblasts

To verify the extent to which TAK1 is required for the induction of TGFβ1-responsive mRNAs in human gingival fibroblasts, cells were treated with or without TGFβ1 (6 hours, 4 ng/ml) in the presence of either (5Z)-7-Oxozeaenol inhibitor or DMSO (vehicle). RNAs were extracted and subjected to gene expression profiling using GeneChip Human Gene 1.0 ST arrays. Of the 28,869 genes on the Human GeneChip Gene 1.0 ST Arrays, 147 genes were up-regulated greater or equal to 1.7-fold in response to TGFβ1. Of these, 139 genes were (5Z)-7-Oxozeaenol-sensitive, suggesting that TAK1 mediates essentially all transcriptional responses to TGFβ1 in gingival fibroblasts (Fig 4A). Functional cluster analysis of the 139 (5Z)-7-Oxozeaenol-sensitive mRNAs revealed that those genes affected were included in clusters involved in a hyperproliferative fibrotic response, including mRNAs encoding genes involved with migration/cell adhesion, wound healing and cell cycle/proliferation (Table 1).

Of the genes detected by microarray analysis to be sensitive to TAK1 inhibition, junB transcription factor (JUNB), platelet-derived growth factor-α (PGDFA), endothelin-1 (EDN1), insulin-like growth factor binding protein 3 (IGFBP3), plasminogen activator-inhibitor-1...
PAI-1/SERPINE1, Platelet-derived growth factor-α-polypeptide (PDGFA) and interleukin-11 (IL-11) were selected for further analysis and validation by real time PCR. Endothelin-1 and junB were selected based on their known association in fibrosis and in pro-fibrotic programming in response to TGF-β\[21–24\]. PGDFA was selected as this protein promotes tissue repair and fibrosis [25]. Moreover, IGFBP-3 promotes TGF-β-dependent stromal remodeling [26], PAI-1/SERPINE1 contributes to excessive collagen deposition in wounds [27] and IL-11 is involved with TGF-β signaling and pulmonary myofibroblast activation [28]. In all cases, real time PCR analysis verified the microarray data showing that induction of these mRNAs in

Fig 4. (5Z)-7-oxozeaenol inhibits TGFβ1-induced mRNA expression in human gingival fibroblasts. (A) Human gingival fibroblasts were serum starved overnight and pre-treated with (5Z)-7-oxozeaenol (400 nM) or DMSO for 45 min followed by treatment with TGFβ1 (4ngml\(^{-1}\) (90 pM)) ligand or left untreated. Total RNA was harvested six hours later and subjected to gene expression profiling using GeneChip Human Gene 1.0 ST arrays (N = 2) as described in Methods. 147 genes were up-regulated in response to TGFβ1 (1.7 fold induction compared to DMSO control group) and 139 genes of the latter group were found to be (5Z)-7-Oxozeaenol sensitive. (B) Human gingival fibroblasts were treated as in (A) and subject to TaqMan RT-qPCR analysis using the indicated probe/primer set. 18S RNA was used as the internal control. (N = 3; averages +/-SEM are shown. * = p<0.05; ** = p<0.01; *** = p<0.001, One-Way ANOVA).

doi:10.1371/journal.pone.0123689.g004
| Affymetrix ID | GENBANK ACCESSION | Gene name                                      | Fold Increase |
|---------------|-------------------|------------------------------------------------|---------------|
| 8116921       | AK291838          | endothelin 1                                   | 6.7818        |
| 8024485       | AF078077          | growth arrest and DNA-damage-inducible, beta   | 2.39958       |
| 8139207       | AK290584          | inhibin, beta A                                | 2.04306       |
| 8026047       | BC004250          | jun B proto-oncogene                            | 1.87672       |
| 7922976       | AK292167          | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | 1.92186 |
| 8147012       | BC022265          | protein kinase (cAMP-dependent, catalytic) inhibitor alpha | 2.41012 |
| 8040473       | AF498971          | ras homolog gene family, member B              | 1.88318       |
| 8010061       | AF200328          | sphingosine kinase 1                           | 1.72518       |
|               |                   |                                               |               |
| Affymetrix ID | GENBANK ACCESSION | Gene name                                      | Fold Increase |
| 8023220       | AF010193          | SMAD family member 7                           | 2.841         |
| 8160837       | AK297541          | UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 | 2.12002 |
| 8116921       | AK291838          | endothelin 1                                   | 6.7818        |
| 8072678       | BC001491          | heme oxygenase (decycling) 1                   | 2.05866       |
| 8114572       | BC033097          | heparin-binding EGF-like growth factor         | 4.0607        |
| 8139488       | AK298143          | insulin-like growth factor binding protein 3   | 1.88748       |
| 8137670       | AK292217          | platelet-derived growth factor alpha polypeptide | 2.07886 |
| 8010061       | AF200328          | sphingosine kinase 1                           | 1.72518       |
| 8148304       | AF205437          | tribbles homolog 1 (Drosophila)                | 2.96456       |
| 7962579       | AY454159          | adhesion molecule with Ig-like domain 2        | 3.45511       |
| 8022674       | BC036470          | cadherin 2, type 1, N-cadherin (neuronal)       | 2.04821       |
| 8035517       | AK074508          | cartilage oligomeric matrix protein            | 3.02008       |
| 8121685       | AJ420528          | discoidin, CUB and LCCL domain containing 1    | 1.85226       |
| 8056184       | AK290300          | integrin, beta 6                               | 2.41065       |
| 8102232       | AF198532          | lymphoid enhancer-binding factor 1             | 1.90975       |
| 8123936       | AK292682          | neural precursor cell expressed, developmentally down-regulated | 2.93624 |
| 8047732       | AL833606          | neuropilin 2                                   | 1.73487       |
| 8040473       | AF498971          | ras homolog gene family, member B              | 1.88318       |

Wound healing cluster

| Affymetrix ID | GENBANK ACCESSION | Gene name                                      | Fold Increase |
|---------------|-------------------|------------------------------------------------|---------------|
| 7950933       | AB041035          | NADPH oxidase 4                                 | 8.49418       |
| 8160637       | AK297541          | UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 | 2.12002 |
| 8072678       | BC001491          | heme oxygenase (decycling) 1                   | 2.05866       |
| 8114572       | BC033097          | heparin-binding EGF-like growth factor         | 4.0607        |
| 8056184       | AK290300          | integrin, beta 6                               | 2.41065       |
| 8039484       | AK290572          | interleukin 11                                 | 1.84543       |
| 8137670       | AK292217          | platelet-derived growth factor alpha polypeptide | 2.07886 |
| 8135069       | AK293248          | serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | 2.17387 |

Genes involved with a hyperproliferative response are shown.

doi:10.1371/journal.pone.0123689.t001
response to TGFβ was reduced by (5Z)-7-Oxozeaenol (Fig 4B). Conversely, baseline (i.e., unin-duced) mRNA expression was not significantly affected by (5Z)-7-Oxozeaenol (Fig 3B).

(5Z)-7-Oxozeaenol reduces gingival fibroblast proliferation

Having established that the cluster involved with proliferation was affected by (5Z)-7-Oxozeaenol, we performed a functional validation of this result using a BrdU-based proliferation assay (Fig 5). Compared to DMSO alone, TGFβ1 treatment resulted in increased proliferation that was sensitive to (5Z)-7-oxo. These results are consistent with the hypothesis that TAK1 controls fibroproliferative responses in gingival fibroblasts.

Conclusions

TGFβ promotes wound healing and fibrotic responses in vitro and in vivo [5]. Fibroblast activation in response to TGFβ1 involves both canonical ALK5/Smad-dependent and
non-canonical Smad-independent pathways [5]. An example of a non-canonical pathway is the TAK1 pathway, which mediates p38 and JNK phosphorylation in response to TGFβ [29]. Previously, we used the selective TAK1 inhibitor 5Z-7-Oxozeanol to show that, in human dermal fibroblasts, the non-canonical TAK1 pathway mediates the induction of ~70% of the mRNAs in response to TGFβ1, including pro-fibrotic gene expression clusters [13]. Specifically, in this previous study, induction of 741/1049 TGFβ1-inducible transcripts were sensitive to (5Z)-7-Oxozeanol and wound healing and ECM clusters were found to be sensitive to 5Z-7-Oxozeanol [13]. In this report, we extend these prior reports by using 5Z-7-Oxozeanol to show that the non-canonical TAK1 pathway mediates essentially all transcriptional responses to TGFβ1 in gingival fibroblasts. 5Z-7-Oxozeanol also blocked the ability of TGFβ1-induced CCN2 mRNA and protein expression as well TGFβ-induced collagen type I protein and proliferation. Thus the TAK1 pathway is operant in gingival fibroblasts and mediates fibroproliferative responses to TGFβ in this cell type.

Unlike skin, gingiva do not scar in response to fibrogenic stimuli. Fibrotic responses in gingival fibroblasts are largely fibroproliferative but not fibrocontractile and hence are neither characterized by scar tissue or by abundant myofibroblasts, the cell type believed to be responsible for scar tissue formation and chronic fibrosis [30–32]. It is interesting to note, however, that in both dermal and gingival fibroblasts, the TAK1-mediated pathway operates and, in both cell types, mediates fibroproliferative responses to TGFβ. Thus a failure of the TAK1 pathway to operate in gingival fibroblasts is not likely to be the basis underlying scarless repair. An emerging body of evidence links excess mechanical loading/stimulation to scar tissue formation [33–36]. Indeed, gingival fibroblasts inherently show reduced expression of pro-adhesive and pro-contractile genes both basally and in response to TGFβ; these features have been linked to reduced activation of the pro-adhesive signaling pathway [16, 30, 37]. Hence alterations in expression of mechanotransductive proteins may underlie basis for scarless repair. Nonetheless, our current results are consistent with the hypothesis that TAK1 inhibitors such as (5Z)-7-Oxozeanol may be considered, in the future, for treating disorders characterized by fibroproliferative responses such as gingival hyperplasia.

**Author Contributions**

Performed the experiments: HK JH HMM. Analyzed the data: HK JH HMM DC. Contributed reagents/materials/analysis tools: DC. Wrote the paper: HK JH DC AL.

**References**

1. Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Research & Therapy 2007; 9: S4.

2. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214:199–210. PMID: 18161745

3. Eddy RJ, Petro JA, Tomasek JJ. Evidence for the nonmuscle nature of the "myofibroblast" of granulation tissue and hypertropic scar. An immunofluorescence study. Am J Pathol. 1988; 130:252–60. PMID: 3277440

4. Uzel MI, Kantarci A, Hong HH, Uygur C, Sheff MC, Firtelli E, Trackman PC. Connective tissue growth factor in drug-induced gingival overgrowth. J Periodontol. 2001; 72: 921–31 PMID: 11495141

5. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004; 18: 816–827. PMID: 15117886

6. Thompson K, Hamilton DW, Leask A. ALK5 Inhibition Blocks TGF β-induced CCN2 Expression in Gingival Fibroblasts. J Dent Res 2010; 89: 1450–1454. doi: 10.1177/0022034510379020 PMID: 20924066

7. Thompson K, Murphy-Marshman H, Leask A. ALK5 inhibition blocks TGFβ-induced CCN1 expression in human foreskin fibroblasts. J Cell Commun Signal. 2014; 8:59–63. doi: 10.1007/s12079-014-0229-7 PMID: 24567145
8. Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, et al. Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem. 2001; 276:19945–53. PMID:11262418

9. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem. 2001; 276:10594–601. PMID:11152469

10. Leask A, Sa S, Holmes A, Shiwen X, Black CM, Abraham DJ. The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol. 2001; 54:180–3 PMID:11376132

11. Landström M. The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol. 2010: 42: 585–9. doi:10.1016/j.biocel.2009.12.023 PMID: 20060931

12. Shi-wen X, Parapumur SK, Pala D, Chen Y, Carter DE, Eastwood M, et al. Requirement of Transforming Growth Factor beta-Activated Kinase 1 for Transforming Growth Factor beta-Induced alpha-Smooth Muscle Actin Expression and Extracellular Matrix Contraction in Fibroblasts. Arthritis Rheum 2009; 60: 234–241. doi:10.1002/art.24223 PMID: 19116914

13. Guo F, Hutchenerreuther J, Carter DE, Leask A. TAK-1 is required for dermal wound healing and homeostasis. J Invest Dermatol. 2013; 133:1646–54. doi:10.1038/jid.2013.28 PMID: 23340735

14. Shi-wen X, Parapumur SK, Pala D, Carter DE, Eastwood M, et al. Requirement of Transforming Growth Factor beta-Activated Kinase 1 for Transforming Growth Factor beta-Induced alpha-Smooth Muscle Actin Expression and Extracellular Matrix Contraction in Fibroblasts. Arthritis Rheum 2009; 60: 234–241. doi:10.1002/art.24223 PMID: 19116914

15. Nakerakanti SS, Kapanadze B, Yamasaki M, Markiewicz M, Trojanowska M. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem. 2006; 281:25259–69 PMID: 16829517

16. Black SA Jr, Trackman PC. Transforming growth factor-beta1 (TGFbeta1) stimulates connective tissue growth factor (CCN2/CTGF) expression in human gingival fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent mechanism: statins with forskolin block TGFbeta1-induced CCN2/CTGF expression. J Biol Chem 2008; 283:10835–47 doi:10.1074/jbc.M710363200 PMID: 18287089

17. Liu J, Pampillo M, Guo F, Liu S, Cooperman BS, Farrell I, et al. Monitoring collagen synthesis in fibroblasts using fluorescently labeled RNA pairs. J Cell Physiol. 2014; 229:1121–9 doi:10.1002/jcp.24630 PMID: 24676899

18. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of Endothelin-1 and its Binding-Sites in Scleroderma Skin. J Rheumatol 1994; 21:1268–76. PMID: 7525957

19. Shi-wen X, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, et al. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem 2004; 279:23098–23103 PMID: 15044479

20. Mauriel A, Chen YQ, Dong W, Evans CH, Uitto J. Transcriptional interactions of transforming growth-factor-beta with pro-inflammatory cytokines. Curr Biol 1993; 3:822–831. PMID: 15335815

21. Mauriel A, Chung KY, Agarwal A, Tamai K, Uitto J. Cell-specific induction of distinct oncogenes of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-beta in fibroblasts and keratinocytes. J Biol Chem 1996; 271:10917–10923. PMID: 8631909

22. Leask A. Possible strategies for anti-fibrotic drug intervention in scleroderma. J Cell Commun Signal. 2011; 5:125–9 doi:10.1007/s12079-011-0122-6 PMID: 21484189

23. Sampson N, Zenzmaier C, Heitz M, Hermann M, Plas E, Schäfer G, et al. Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation. Endocrinology. 2013; 154: 2586–99. doi: 10.1210/en.2012-2259 PMID: 23720424

24. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol 2012; 227:493–507 doi: 10.1002/jcp.22783 PMID: 21465481
28. Moodley YP, Misso NLA, Scaffidi AK, Fogel-Petrovic M, McAnulty RJ, Laurent GJ, et al. Inverse Effects of Interleukin-6 on Apoptosis of Fibroblasts from Pulmonary Fibrosis and Normal Lungs. Am J Respir Cell Mol Biol 2003; 29: 490–498. PMID: 12714376

29. Mu Y, Gudey SK, Landström M. Non-Smad signaling pathways. Cell Tissue Res. 2012; 347:11–20. doi: 10.1007/s00441-011-1201-y PMID: 21701805

30. Mah W, Jiang G, Olver D, Cheung G, Kim B, Larjava H, et al. Human gingival fibroblasts display a non-fibrotic phenotype distinct from skin fibroblasts in three-dimensional cultures. PLOS One.2014; 9: e90715. doi: 10.1371/journal.pone.0090715 PMID: 24608113

31. Bitu CC, Sobral LM, Kellermann MG, Martelli-Junior H, Zecchin KG, Graner E, et al. Heterogeneous presence of myofibroblasts in hereditary gingival fibromatosis. J Clin Periodontol. 2006; 33:393–400 PMID: 16677327

32. Damasceno LS, Gonçalves Fda S, Costa e Silva E, Zenóbio EG, Souza PE, Horta MC. Stromal myofibroblasts in focal reactive overgrowths of the gingiva. Braz Oral Res. 2012; 26:373–7 PMID: 22714931

33. Van De Water L, Varney S, Tomasek JJ. Mechanoregulation of the Myofibroblast in Wound Contraction, Scarring, and Fibrosis: Opportunities for New Therapeutic Intervention. Adv Wound Care (New Rochelle). 2013; 2:122–141.

34. Liu S, Kapoor M, Denton CP, Abraham DJ, Leask A Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum. 2009; 60:2817–21 doi: 10.1002/art.24801 PMID: 19714619

35. Achterberg VF, Buscemi L, Diekmann H, Smith-Clerc J, Schwengler H, Meister JJ, et al. The nanoscale mechanical properties of the extracellular matrix regulate dermal fibroblast function. J Invest Dermatol. 2014; 134:1862–72. doi: 10.1038/jid.2014.90 PMID: 24670384

36. Wong VW, Rustad KC, Akaishi S, Sorkin M, Glotzbach JP, Januszky M, et al. Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. Nat Med. 2011; 18:148–52 doi: 10.1038/nm.2574 PMID: 22157678

37. Guo F, Carter DE, Mukhopadhyay A, Leask A. Gingival Fibroblasts Display Reduced Adhesion and Spreading on Extracellular Matrix: A Possible Basis for Scarless Tissue Repair? PLOS One 2011; 6: e27097. doi: 10.1371/journal.pone.0027097 PMID: 22073262